HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

Phase 2BGE-102Positive

AI Analysis

Summary

BioAge Labs, in partnership with HitGen, has dosed the first participant in a Phase 2 trial of BGE-102, an oral NLRP3 inhibitor being developed for cardiovascular risk reduction.

Clinical Trial Data

Phase

Phase 2

Outcome Details

first participant dosed in Phase 2 trial

Importance:6/10

Sentiment:

0.60

NLRP3 inhibitororal therapycardiovascularPhase 2 initiationpartnership

Related Companies

$BIOA

Read the original article

Published by PR Newswire Pharma on July 14, 2026 8:30 AM

Read Original